What is the MELD Score?
MELD = 3.78×ln(bilirubin) + 11.2×ln(INR) + 9.57×ln(creatinine) + 6.43
Calculate MELD Score (Model for End-Stage Liver Disease) to assess liver disease severity and transplant prioritization. Scientifically validated tool.
This calculator is an educational and clinical decision support tool. Results DO NOT replace professional medical evaluation, laboratory tests, or clinical judgment. Always consult a qualified healthcare professional for diagnosis, treatment, and clinical decisions. Calculations are based on scientifically validated formulas but may not be applicable to all patients.
Note: MELD is a prognostic tool. Transplant decisions consider multiple clinical factors, including complications not captured by MELD (encephalopathy, refractory ascites, hepatopulmonary syndrome). Always consult a hepatologist or transplant surgeon.
MELD (Model for End-Stage Liver Disease) is a prognostic score developed to assess chronic liver disease severity. It uses three objective laboratory tests (creatinine, bilirubin, and INR) to estimate 90-day mortality without transplant. Initially created to predict mortality after TIPS (transjugular intrahepatic portosystemic shunt), MELD was validated as a survival predictor in cirrhosis and is now the primary criterion for liver allocation in most countries. The mathematical formula assigns greater weight to creatinine and INR, reflecting that renal dysfunction and coagulopathy are independent mortality predictors.
MELD = 3.78×ln(bilirubin) + 11.2×ln(INR) + 9.57×ln(creatinine) + 6.43
To calculate MELD: 1) Obtain most recent laboratory values: Serum creatinine (mg/dL), Total bilirubin (mg/dL), INR. 2) Check if patient underwent dialysis in the last 72 hours (in this case, creatinine is considered 4.0 mg/dL). 3) Apply minimum values: Creatinine <1.0 = 1.0, Bilirubin <1.0 = 1.0, INR <1.0 = 1.0. 4) Apply maximum values: Creatinine >4.0 = 4.0. 5) Enter values in calculator. Result ranges from 6 (lowest severity) to 40 (highest severity). IMPORTANT: Use values in mg/dL. If your labs provide μmol/L, convert: Creatinine (μmol/L) ÷ 88.4 = mg/dL; Bilirubin (μmol/L) ÷ 17.1 = mg/dL.
90-day mortality: <2%. Compensated cirrhosis without clinical decompensation. Generally not transplant candidates. Focus on etiologic treatment (alcohol abstinence, antivirals for hepatitis, etc.) and regular outpatient follow-up.
90-day mortality: 6-20%. Cirrhosis with some degree of decompensation. MELD 10-14: Consider transplant listing if complications (ascites, encephalopathy). MELD 15-19: Transplant candidates, but waiting time may be long depending on region.
90-day mortality: 20-50%. Severe decompensated cirrhosis. Priority transplant candidates. MELD ≥15 is considered cutoff for transplant indication in most centers. Requires hospitalization or intensive follow-up.
90-day mortality: >50%. Severe liver failure. High transplant priority. MELD ≥35: Mortality >80% at 90 days. Often requires ICU care. Consider living donor listing or regional/national prioritization.
Child-Pugh (A, B, C) was the first cirrhosis severity classification, using 5 parameters: bilirubin, albumin, INR, ascites, and encephalopathy. It's subjective (ascites and encephalopathy are clinical) and has a ceiling (Child C may include patients of very variable severity). MELD is totally objective (labs only), continuous (6-40), and better mortality predictor. Therefore, it replaced Child-Pugh for transplant allocation. Child-Pugh is still used for prognosis in compensated cirrhosis and classification in clinical trials.
In listed transplant patients: Every 7 days if MELD ≥25 (high priority), every 30 days if MELD 19-24, every 90 days if MELD <19. In non-listed patients: Recalculate in acute decompensations (infection, bleeding, renal failure), before surgical procedures, and every 3-6 months in outpatient cirrhosis follow-up.
Yes. MELD doesn't capture all complications. Refractory ascites (not responding to diuretics), hepatopulmonary syndrome, recurrent encephalopathy, and recurrent spontaneous bacterial peritonitis are transplant indications even with 'low' MELD. In these cases, MELD exception can be requested from transplant program with detailed clinical justification.
No. MELD was developed for CHRONIC liver disease. In acute liver failure (fulminant hepatitis), use King's College Criteria (more appropriate). These consider encephalopathy, INR, creatinine, pH, and etiology. MELD may underestimate severity in fulminant hepatitis, as bilirubin may not be very elevated in early stages.
Yes, PELD (Pediatric End-Stage Liver Disease) is used in children <12 years. The formula is different, including: bilirubin, INR, albumin, age (<1 year gains extra points), and presence of growth failure. PELD reflects that children with cirrhosis have different pathophysiology and prognosis than adults.
MELD = 3.78×ln(bilirubin) + 11.2×ln(INR) + 9.57×ln(creatinine) + 6.43